Back to Atlas
BSemi-durableStandard research/education caution
CMP-0633
Research chemical/reference listing
Forigerimod
Immune modulation
Immune balance, inflammation, or resilience support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Immune / inflammatory modulator
- Primary mechanism
- Immune or inflammatory pathway modulation
- Primary market use
- Immune modulation
Pharmacology
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy . Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .